NEW YORK (GenomeWeb) – Rubicon Genomics today announced that it has extended a clinical supply agreement providing its TransPlex whole-genome RNA amplification technology to Agendia for use in its MammaPrint 70-Gene breast cancer recurrence assay.

In early 2012, Agendia first inked the deal to use Rubicon's technology to analyze formalin-fixed, paraffin-embedded (FFPE) breast cancer samples on its Symphony suite of diagnostics, which includes MammaPrint.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.